Mr. Rudnick has over 35 years of experience in executive-level strategy, finance, and management, including in biotech companies. He himself has co-founded several companies, including CapGenic Advisors, LLC, and a number of start-ups, three of which grew to over $60 million in revenue before exiting. He is also a founder of one of the US’s leading entrepreneurial programs (MADV) at the Fox School of Business in Philadelphia. Working with businesses ranging from start-ups to Fortune 50 companies, Mr. Rudnick has developed extensive experience in senior merger, acquisition, capital formation and licensing leadership. He also has substantial experience investing and guiding investments in entrepreneurial companies, and has led capital formation totaling more than $530 million in the past ten years and $3 billion over the last 15 years. As an adviser to companies in the fields of clinical software, therapeutic, medical device, and cell line engineering, Mr. Rudnick’s clients have included Mitsui (Mitrix), DuPont (Agri-chemical), McKesson Bioservices (now TMO), Kika Clinical Solutions (now MRGE). He is also affiliated with several angel groups, including Minority Angel Investment Network, Mid-Atlantic Bio Angels (which he co-founded) and Keiretsu Mid-Atlantic.

Life sciences